antimicrobial resistance clinical microbiology publication tuberculosis

New publication: Validating a bespoke 96-well plate for high-throughput drug susceptibility testing of M. tuberculosis

This paper, published in Antimicrobial Agents and Chemotherapy, determines the reproducibility and accuracy of minimum inhibitory concentrations for a panel of 14 different anti-TB compounds using a specifically designed 96-well plate (called UKMYC5) manufactured by Thermo Fisher.

Since the UKMYC5 plate is being used by the CRyPTIC consortium to measure the drug susceptibility profiles of >30,000 clinical TB samples collected worldwide between now and 2020, this manuscript lays the foundations for this large and ambitious tuberculosis research project.

It is free to read and download, and the paper briefly mentions my AMyGDA software which we will be using as an independent measuring technique to quality control the measurements made by the laboratory scientists. You can download and AMyGDA software from here. A manuscript is currently under review – you can read a preprint here.

The bacterial growth on the UKMYC5 plates are also being classified by a Citizen Science project I have setup, BashTheBug.

By Philip Fowler

Philip W Fowler is a computational biophysicist studying antimicrobial resistance working at the John Radcliffe Hospital in Oxford.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.